163 related articles for article (PubMed ID: 16504693)
1. Bisphosphonates are effective prophylactic of early bone loss after renal transplantation.
Nowacka-Cieciura E; Cieciura T; Baczkowska T; Kozińska-Przybył O; Tronina O; Chudziński W; Pacholczyk M; Durlik M
Transplant Proc; 2006; 38(1):165-7. PubMed ID: 16504693
[TBL] [Abstract][Full Text] [Related]
2. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
3. Effect of bisphosphonates on bone mineral density after renal transplantation as assessed by bone mineral densitometry.
Nayak B; Guleria S; Varma M; Tandon N; Aggarwal S; Bhowmick D; Agarwal SK; Mahajan S; Gupta S; Tiwari SC
Transplant Proc; 2007 Apr; 39(3):750-2. PubMed ID: 17445589
[TBL] [Abstract][Full Text] [Related]
4. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
[TBL] [Abstract][Full Text] [Related]
5. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
6. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
7. [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism].
Yang LJ; Shen FX; Zheng JC; Zhang HL
Zhongguo Gu Shang; 2012 Feb; 25(2):133-7. PubMed ID: 22577718
[TBL] [Abstract][Full Text] [Related]
8. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of osteoporosis, osteopenia, and vertebral fractures in long-term renal transplant recipients.
Marcén R; Caballero C; Uriol O; Fernández A; Villafruela JJ; Pascual J; Martins J; Rodriguez N; Burgos FJ; Ortuño J
Transplant Proc; 2007 Sep; 39(7):2256-8. PubMed ID: 17889156
[TBL] [Abstract][Full Text] [Related]
10. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
12. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
[TBL] [Abstract][Full Text] [Related]
14. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
15. Weekly risedronate in kidney transplant patients with osteopenia.
Torregrosa JV; Fuster D; Pedroso S; Diekmann F; Campistol JM; Rubí S; Oppenheimer F
Transpl Int; 2007 Aug; 20(8):708-11. PubMed ID: 17555530
[TBL] [Abstract][Full Text] [Related]
16. The prevention of bone fractures after liver transplantation: experience with alendronate treatment.
Atamaz F; Hepguler S; Karasu Z; Kilic M; Tokat Y
Transplant Proc; 2006 Jun; 38(5):1448-52. PubMed ID: 16797329
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
18. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.
Walsh SB; Altmann P; Pattison J; Wilkie M; Yaqoob MM; Dudley C; Cockwell P; Sweny P; Banks LM; Hall-Craggs M; Noonan K; Andrews C; Cunningham J
Am J Kidney Dis; 2009 May; 53(5):856-65. PubMed ID: 19393473
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
20. Alendronate is effective to treat bone loss in renal transplantation recipients.
Lan G; Peng L; Xie X; Peng F; Wang Y; Yu S
Transplant Proc; 2008 Dec; 40(10):3496-8. PubMed ID: 19100422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
